Evaluation of cytokine levels as putative biomarkers to predict the pharmacological response to biologic therapy in inflammatory bowel diseases

被引：15

作者：

Bertani, Lorenzo ^{[1
]}

Antonioli, Luca ^{[2
]}

Fornai, Matteo ^{[2
]}

Tapete, Gherardo ^{[1
]}

Baiano Svizzero, Giovanni ^{[1
]}

Marchi, Santino ^{[1
]}

Blandizzi, Corrado ^{[2
]}

Costa, Francesco ^{[3
]}

机构：

[1] Pisa Univ Hosp, Dept Translat Res & New Technol Med & Surg, Unit Gastroenterol, Via Paradisa 2, I-56124 Pisa, Italy

[2] Univ Pisa, Dept Clin & Expt Med, Unit Pharmacol & Pharmacovigilance, Pisa, Italy

[3] Pisa Univ Hosp, Dept Gen Stugery & Gastroenterol, Unit Inflammatory Bowel Dis, Pisa, Italy

来源：

MINERVA GASTROENTEROLOGICA E DIETOLOGICA | 2019年 / 65卷 / 04期

关键词：

Inflammatory bowel diseases; Cytokines; Biological therapy; Tumor biomarkers; NECROSIS-FACTOR-ALPHA; SEVERE CROHNS-DISEASE; ANTI-TNF TREATMENTS; ULCERATIVE-COLITIS; INDUCTION THERAPY; GENE-EXPRESSION; T-CELL; MAINTENANCE THERAPY; MONOCLONAL-ANTIBODY; FECAL CALPROTECTIN;

D O I：

10.23736/S1121-421X.19.02621-7

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Cytokines play a central role in the pathogenesis of inflammatory bowel diseases. For this reason, the vast majority of biological therapies are aimed to block pro-inflammatory cytokines or their receptors. Although these drugs have modified the course of the disease due to their efficacy, a high rate of non-response or loss of response over time is still an important issue for clinicians. In this perspective, many studies have been conducted in recent years to individuate a reliable biomarker of therapeutic response. In this review, we discuss the role of cytokines involved in the pathogenesis and in the therapy of inflammatory bowel diseases, and their putative use as pharmacological biomarkers of therapy responsiveness.

引用

页码：298 / 308

页数：11

共 97 条

[21] Significance of serum Il-9 levels in inflammatory bowel disease [J].

Defendenti, Caterina ;

Sarzi-Puttini, Piercarlo ;

Saibeni, Simone ;

Bollani, Simona ;

Bruno, Savino ;

Almasio, Piero Luigi ;

Declich, Paolo ;

Atzeni, Fabiola .

INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2015, 28 (04) :569-575

[22] Differential IL-10R1 expression plays a critical role in IL-10-mediated immune regulation [J].

Ding, YZ ;

Qin, LH ;

Zamarin, D ;

Kotenko, SV ;

Pestka, S ;

Moore, KW ;

Bromberg, JS .

JOURNAL OF IMMUNOLOGY, 2001, 167 (12) :6884-6892

[23] Cutting edge:: A transcriptional repressor and corepressor induced by the STAT3-regulated anti-inflammatory signaling pathway [J].

El Kasmi, Karim C. ;

Smith, Amber M. ;

Williams, Lynn ;

Neale, Geoffrey ;

Panopolous, Athanasia ;

Watowich, Stephanie S. ;

Haecker, Hans ;

Toxwell, Brian M. J. ;

Murray, Peter J. .

JOURNAL OF IMMUNOLOGY, 2007, 179 (11) :7215-7219

[24] Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease [J].

Feagan, B. G. ;

Sandborn, W. J. ;

Gasink, C. ;

Jacobstein, D. ;

Lang, Y. ;

Friedman, J. R. ;

Blank, M. A. ;

Johanns, J. ;

Gao, L. -L. ;

Miao, Y. ;

Adedokun, O. J. ;

Sands, B. E. ;

Hanauer, S. B. ;

Vermeire, S. ;

Targan, S. ;

Ghosh, S. ;

de Villiers, W. J. ;

Colombel, J. -F. ;

Tulassay, Z. ;

Seidler, U. ;

Salzberg, B. A. ;

Desreumaux, P. ;

Lee, S. D. ;

Loftus, E. V., Jr. ;

Dieleman, L. A. ;

Katz, S. ;

Rutgeerts, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20) :1946-1960

[25] Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study [J].

Feagan, Brian G. ;

Panes, Julian ;

Ferrante, Marc ;

Kaser, Arthur ;

D'Haens, Geert R. ;

Sandborn, William J. ;

Louis, Edouard ;

Neurath, Markus F. ;

Franchimont, Denis ;

Dewit, Olivier ;

Seidler, Ursula ;

Kim, Kyung-Jo ;

Selinger, Christian ;

Padula, Steven J. ;

Herichova, Ivona ;

Robinson, Anne M. ;

Wallace, Kori ;

Zhao, Jun ;

Minocha, Mukul ;

Othman, Ahmed A. ;

Soaita, Adina ;

Visvanathan, Sudha ;

Hall, David B. ;

Boecher, Wulf O. .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (10) :671-680

[26] Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study [J].

Feagan, Brian G. ;

Sandborn, William J. ;

D'Haens, Geert ;

Panes, Julian ;

Kaser, Arthur ;

Ferrante, Marc ;

Louis, Edouard ;

Franchimont, Denis ;

Dewit, Olivier ;

Seidler, Ursula ;

Kim, Kyung-Jo ;

Neurath, Markus F. ;

Schreiber, Stefan ;

Scholl, Paul ;

Pamulapati, Chandrasena ;

Lalovic, Bojan ;

Visvanathan, Sudha ;

Padula, Steven J. ;

Herichova, Ivona ;

Soaita, Adina ;

Hall, David B. ;

Bocher, Wulf O. .

LANCET, 2017, 389 (10080) :1699-1709

[27] Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease [J].

Feng, Ting ;

Chen, Baili ;

Li, Li ;

Huang, Shanshan ;

Ben-Horin, Shomron ;

Qiu, Yun ;

Feng, Rui ;

Li, Manying ;

Mao, Ren ;

He, Yao ;

Zeng, Zhirong ;

Zhang, Shenghong ;

Chen, Minhu .

INFLAMMATORY BOWEL DISEASES, 2017, 23 (10) :1817-1824

[28] Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease [J].

Friedrich, Matthias ;

Pohin, Mathilde ;

Powrie, Fiona .

IMMUNITY, 2019, 50 (04) :992-1006

[29] Increased expression of interleukin 17 in inflammatory bowel disease [J].

Fujino, S ;

Andoh, A ;

Bamba, S ;

Ogawa, A ;

Hata, K ;

Araki, Y ;

Bamba, T ;

Fujiyama, Y .

GUT, 2003, 52 (01) :65-70

[30] Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis [J].

Fuss, IJ ;

Heller, F ;

Boirivant, M ;

Leon, F ;

Yoshida, M ;

Fichtner-Feigl, S ;

Yang, ZQ ;

Exley, M ;

Kitani, A ;

Blumberg, RS ;

Mannon, P ;

Strober, W .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (10) :1490-1497

← 1 2 3 4 5 6 7 8 9 10 →